Evidence map›Paper›PMID 22718200›Full record

ArticleHuman molecular genetics2012

Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity.

Jemima Barrowman, Patricia A Wiley, Sarah E Hudon-Miller, Christine A Hrycyna, Susan Michaelis

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Prelamin A in anArteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Restrictive Dermopathy in Neonates.Indian journal of pediatrics · 2026
    Article
  8. Article
  9. Acyl-CoA-binding protein as a driver of pathological aging.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  20. Molecular Pathology of Laminopathies.Annual review of pathology · 2022
    Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jemima BarrowmanDepartment of Cell Biology, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Patricia A Wiley
Sarah E Hudon-Miller
Christine A Hrycyna
Susan Michaelis
Purdue University West Lafayette · USJohns Hopkins University · US

Funding

The integral membrane protease ZMPSTE24, lamin A processing, and progeriaR01GM041223 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MICHAELIS, SUSAN D. · 1989 to 2017
$5.0M
NIGMS NIH HHS R01 GM41223
6 · The paper itself

Abstract

The zinc metalloprotease ZMPSTE24 plays a critical role in nuclear lamin biology by cleaving the prenylated and carboxylmethylated 15-amino acid tail from the C-terminus of prelamin A to yield mature lamin A. A defect in this proteolytic event, caused by a mutation in the lamin A gene (LMNA) that eliminates the ZMPSTE24 cleavage site, underlies the premature aging disease Hutchinson-Gilford Progeria Syndrome (HGPS). Likewise, mutations in the ZMPSTE24 gene that result in decreased enzyme function cause a spectrum of diseases that share certain features of premature aging. Twenty human ZMPSTE24 alleles have been identified that are associated with three disease categories of increasing severity: mandibuloacral dysplasia type B (MAD-B), severe progeria (atypical 'HGPS') and restrictive dermopathy (RD). To determine whether a correlation exists between decreasing ZMPSTE24 protease activity and increasing disease severity, we expressed mutant alleles of ZMPSTE24 in yeast and optimized in vivo yeast mating assays to directly compare the activity of alleles associated with each disease category. We also measured the activity of yeast crude membranes containing the ZMPSTE24 mutant proteins in vitro. We determined that, in general, the residual activity of ZMPSTE24 patient alleles correlates with disease severity. Complete loss-of-function alleles are associated with RD, whereas retention of partial, measureable activity results in MAD-B or severe progeria. Importantly, our assays can discriminate small differences in activity among the mutants, confirming that the methods presented here will be useful for characterizing any new ZMPSTE24 mutations that are discovered.

Indexed as

MutationProteolysisAllelesAmino Acid SequenceContractureCraniofacial AbnormalitiesLipodystrophyMembrane ProteinsMetalloendopeptidasesModels, MolecularProgeriaSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSkin AbnormalitiesMembrane ProteinsMetalloendopeptidasesSaccharomyces cerevisiae ProteinsSTE24 protein, S cerevisiaeZMPSTE24 protein, human

Identifiers

PMID22718200
PMCPMC3428156
OpenAlexW2146343792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.